Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0

作者：

Giri, Pratyush

Patil, Sushrut

Ratnasingam, Sumita

Prince, H. Miles

Milliken, Samuel

Meijide, Javier Briones

Coyle, Luke

Van der Poel, Marjolein

Mulroney, Carolyn M.

Farooqui, Mohammed Z. H.

Wong, Hansen

Desai, Rajendra

Zugmaier, Gerhard

Mergen, Noemi

Cannell, Paul

机构：

[1] Royal Adelaide Hosp, Adelaide, SA, Australia

[2] Alfred Hosp & Monash Univ, Melbourne, Vic, Australia

[3] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia

[4] Epworth Healthcare, East Melbourne, Australia

[5] Sir Peter MacCallum Canc Inst, East Melbourne, Australia

[6] St Vincents Hosp, Darlinghurst, NSW, Australia

[7] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[8] Royal Northshore Hosp, St Leonards, NSW, Australia

[9] Maastricht Univ, GROW Sch Oncol & Dev Biol, Div Hematol, Dept Internal Med,Med Ctr, Maastricht, Netherlands

[10] Univ Calif San Diego, La Jolla, CA USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Amgen Clin Pharmacol Modeling & Simulat, South San Francisco, CA USA

[13] IQVIA Inc, Biostat Sci, Mumbai, India

[14] Amgen Res Munich GmbH, Munich, Germany

[15] Royal Perth Hosp, Dept Med, Perth, WA, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

19584

引用

页数：1

共 50 条

[1] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Chen, Robert W.
Ansel, Stephen Maxted
Zinzani, Pier Luigi
Vacirca, Jeffrey L.
Lopez-Guillermo, Armando
Hutchings, Martin
Jurczak, Wojciech
Hess, Georg
Le Gouill, Steven
Offner, Fritz
Santoro, Armando
Salles, Gilles A.
Stypinski, Darla
Laird, Douglas
Pavlov, Dmitri
Andreola, Giovanna
Fly, Kolette D.
Woolfson, Adrian
Collins, Graham P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Witzig, Thomas E.
Maddocks, Kami J.
De Vos, Sven
Lyons, Roger M.
Edenfield, William Jeffery
Sharman, Jeff Porter
Vose, Julie
Yimer, Habte Aragaw
Wei, Helen
Chan, Edward M.
Patel, Priti
Di Simone, Christopher
Gandhi, Mitul
Vaughn, Jennifer
Kolibaba, Kathryn
Cheson, Bruce D.
Samaniego, Felipe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[4] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
de Vos, Sven
Reagan, Patrick M.
Patel, Manish R.
Saba, Nakhle S.
Mortlock, Andrew
Cerec, Virginie
Munugalavadla, Veerendra
Acar, Melih
Nuttall, Barrett
Jenkins, David
White, Rafael
Callahan, Megan
Forcina, Alessandra
Roschewski, Mark
Flinn, Ian W.
BLOOD, 2022, 140 : 6635 - 6637
[5] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)
[6] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907
[7] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
Martin, Alejandro
Redondo, Alba M.
Dlouhy, Ivan
Salar, Antonio
Gonzalez-Barca, Eva
Canales, Miguel
Montes-Moreno, Santiago
Ocio, Enrique M.
Lopez-Guillermo, Armando
Caballero, Dolores
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
[8] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
Palomba, M. Lia
Till, Brian G.
Park, Steven I.
Morschhauser, Franck
Cartron, Guillaume
Marks, Reinhard
Shivhare, Mahesh
Hong, Wan-Jen
Raval, Aparna
Chang, Alice C.
Penuel, Elicia
Popplewell, Leslie L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
[9] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Maakaron, Joseph
Asch, Adam S.
Popplewell, Leslie L.
Collins, Graham P.
Flinn, Ian W.
Ghosh, Nilanjan
Keane, Colin
Ku, Matthew
Mehta, Amitkumar
Roschewski, Mark
O'Hear, Carol
Ren, Xuehan
Villa, Bertha
Lal, Indu
Smith, Sonali M.
Advani, Ranjana H.
BLOOD, 2022, 140 : 3728 - 3730
[10] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →